Retinopathy of prematurity and pulse oximetry: A national survey of recent pratices

被引：92

作者：

Anderson C.G. ^{[1
]}

Benitz W.E. ^{[1
]}

Madan A. ^{[1
]}

机构：

[1] Division of Neonatology, Department of Pediatrics, Stanford Univ. School of Medicine, Palo Alto, CA 94304

来源：

Journal of Perinatology | 2004年 / 24卷 / 3期

关键词：

D O I：

10.1038/sj.jp.7211067

中图分类号：

学科分类号：

摘要：

Objective: To determine if practices related to the use of pulse oximetry in the first 2 weeks following birth and after 2 weeks of age have a relationship to the rate of retinopathy (ROP) and retinal ablation surgery in infants ≤1 1500 g. Study of Design: A questionnaire was mailed in July 2001 to 318 neonatal intensive care units (NICUs) in the United States and information was collected regarding SpO2 guidelines and the rate of both severe ROP and retinal ablation surgery. Results: A total of 142 surveys returned (45%). In all, 87% of the NICUs had SpO2 guidelines, and 60% of these centers maintained a different range of SpO2 for infants ≤ or > 2 weeks of age. The range of SpO2 was 82 to 100% with an average minimum (min) and maximum (max) of 89 and 95%, respectively. In the NICUs with an SpO2 max of >98% in the first 2 weeks following birth, the rate of retinal ablation surgery was 5.5 vs 3% in those units with a max SpO2 >98% (p<0.05). After 2 weeks of age, the rate of retinal the max SpO2 was ≤ 92% (p<0.00001). The rate of ≥stage 3 ROP after 2 weeks of age was 5.5% when max SpO2 was > 92 vs 2.4% when max SpO2 was ≤92% (p<0.0005). Conclusion: NICUs in the US today have wide range of SpO2 guidelines. The results of this survey show "gradient of risk" towards less retinal ablation surgery when the max SpO2 is <98% in the first 2 weeks following birth (p<0.05). There was a statistically significant lower rate of ≥ stage 3 ROP and retinal ablation surgery when the max SPO2 was ≤ 92% after the first 2 weeks of age. A randomized, controlled trial is needed to establish a safe upper limit of SpO2 in the premature infant at risk for developing ROP. © 2004 Nature Publishing Group All rights reserved.

引用

页码：164 / 168

页数：4

共 29 条

[1]

Palmer E.A., Flynn J.T., Hardy R.J., Et al., Incidence and early course of retinopathy of prematurity, Ophthalmology, 98, pp. 1628-1640, (1991)

[2]

Phelps D.L., Part three retinopathy of prematurity, Neonatal-perinatal Medicine Diseases of the Fetus and Infant, pp. 1595-1602, (2002)

[3]

Gunn T.R., Eastdown J., Outerbridge E.W., Aranda J.V., Risk factors in retrolental fibroplasia, Pediatrics, 65, pp. 1096-1100, (1980)

[4]

Bedrossian R.H., Carmichael P., Ritter A., Retinopathy of prematurity (retrolental fibroplasia) and oxygen: Part 1. Clinical study: Part II. Further observations on the disease, An. J. Ophthalmol., 37, pp. 78-86, (1954)

[5]

Kinsey V.E., Retrolental fibroplasia: Cooperative study of retrolental fibroplasia and the use of oxygen, Arch. Ophthalmol., 56, pp. 481-543, (1956)

[6]

Flynn J.T., Bancalari E., Bawol R., Et al., Retinopathy of prematurity. A randomized, prospective trial of transcutaneous oxygen monitoring, Ophthalmology, 94, pp. 630-638, (1987)

[7]

Flynn J.T., Retinopathy of prematurity, Periatr. Clin. North Am., 34, 6, pp. 1487-1516, (1987)

[8]

Hunter D.G., Mulcai S., Retinopathy of prematurity: Pathogenesis, diagnosis and treatmen, Int. Ophthalmol. Clin., 32, 1, pp. 163-184, (1992)

[9]

Pierce E.A., Avery R.L., Foley E.D., Et al., Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, Proc. Natl. Acad. Sci. USA, 92, pp. 905-909, (1995)

[10]

Alon T., Hemo I., Itin A., Et al., Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity, Nat. Med., 1, pp. 1024-1028, (1995)

← 1 2 3 →